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1231The mechanistic insights of [18F]-LMI1195 uptake
assessed in an isolated heart model might be relevant
in the design of clinical imaging protocols, as well as
the interpretation of imaging results in patients.
However, further complementary in vivo animal ex-
periments are needed to conﬁrm and extended these
ﬁndings for clinical studies.Takahiro Higuchi, MD, PhD*
Behrooz H. Youseﬁ, PhD
Sybille Reder, MT
Monika Beschorner, MT
Iina Laitinen, PhD
Ming Yu, MD
Simon Robinson, PhD
Hans Jürgen Wester, PhD
Markus Schwaiger, MD
Stephan G. Nekolla, PhD
*Department of Nuclear Medicine
University of Würzburg
Oberdürrbacher Strasse 6
D-97080 Würzburg
Germany
E-mail: higuchi_t@klinik.uni-wuerzburg.de
http://dx.doi.org/10.1016/j.jcmg.2014.11.013
Please note: Drs. Yu and Robinson are employees of Lantheus Medical Imaging.
All other authors have reported that they have no relationships relevant to the
contents of this paper to disclose. Drs. Higuchi and Youseﬁ contributed equally
to this work.RE F E RENCE S
1. Yu M, Bozek J, Lamoy M, et al. Evaluation of LMI1195, a novel 18F-labeled
cardiac neuronal PET imaging agent, in cells and animal models. Circ Car-
diovasc Imaging 2011;4:435–43.
2. Higuchi T, Youseﬁ BH, Kaiser F, et al. Assessment of the 18F-labeled PET
tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med
2013;54:1142–6.
3. Sinusas AJ, Lazewatsky J, Brunetti J, et al. Biodistribution and ra-
diation dosimetry of LMI1195: ﬁrst-in-human study of a novel 18F-
labeled tracer for imaging myocardial innervation. J Nucl Med 2014;55:
1445–51.Novel Use of Cardiac Magnetic Resonance
Imaging for the Diagnosis of Cobalt
CardiomyopathyA 54-year-old male patient with bilateral metal-
on-metal hip prosthesis and recently diagnosed
cobalt toxicity presented with gradually worsening
symptoms of heart failure. Serum cobalt (120 mg/l;
normal<1 mg/l) and chromium (108.8 mg/l; normal<1.4
mg/l) levels were signiﬁcantly elevated. Echocardio-
gram showed biventricular dysfunction (Online
Video 1), and coronary angiogram was normal.
Contrast-enhanced cardiac magnetic resonance (CMR)was performed for further evaluation of the non-
ischemic cardiomyopathy.
CMR showed severe biatrial enlargement with
reduced left ventricular ejection fraction (36%) and
right ventricular ejection fraction (39%) (Online
Video 2). Black-blood T2 images showed diffuse
increased signal intensity (Figures 1A and 1B) and
imaging after late gadolinium enhancement (LGE)
revealed diffuse hyperenhancement of the left
ventricle (Figures 1C and 1D).
Endomyocardial biopsy was performed (Figures 1E
and 1F). Iron, Congo red, and thioﬂavin T stains for
amyloid were negative. The patient underwent
replacement of both hip prostheses, which were found
to be surrounded in brown creamy ﬂuid indicative of
metallic debris. After surgery, cobalt (16.6 mg/l) and
chromium (32 mg/l) levels declined. Repeat CMR was
performed 5 months later and did not show any
improvement in biventricular function, T2 imaging, or
LGE. The patient continued to decline clinically and
needed left ventricular assist device implantation.
The degree of hyperenhancement seen indicated
a systemic etiology for the cardiomyopathy. This
pattern of hyperenhancement is typically seen with
cardiac amyloidosis; however, the blood pool ki-
netics were not consistent with amyloidosis. The
toxic levels of cobalt and chromium and the
absence of an alternative cause make cobalt car-
diomyopathy the most likely diagnosis. The diffuse
enhancement on LGE represented the diffuse
ﬁbrosis as seen on the endomyocardial biopsy in the
patient and also seen in other reported cases (1,2).
To our knowledge, this is the ﬁrst report of using
CMR in a patient with suspected cobalt cardiomyopa-
thy. Because there are no conﬁrmatory tests for
this diagnosis (2), our ﬁndings suggest that CMR
may have a role in establishing the diagnosis of
cobalt cardiomyopathy. Moreover, in most previously
described case reports (2,3), surgical removal of the
metal-on-metal hip prosthesis resulted in clinical
improvement. However, in our patient, despite
a decrease in serum cobalt and chromium con-
centrations post-surgery, there was continued clinical
deterioration. It is possible that the CMR ﬁndings as
seen inourpatientmaybe indicativeofapoorprognosis
in patients with cobalt cardiomyopathy.Huma Y. Samar, MD*
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FIGURE 1 CMR Images and Biopsy Findings
(A and B) T2-weighted spin echocardiogram images in 4-chamber and short-axis views, respectively, showing diffusely increased signal in-
tensity in the right and left ventricles. The left ventricular myocardial to skeletal muscle T2 ratio was 3:1 (normal <1.9). (C and D) Late
gadolinium enhancement images in 4-chamber and short-axis views, respectively, showing marked diffuse biventricular hyperenhancement in a
transmural pattern with sparing of the basal and mid septum. (E) Endomyocardial biopsy. Groups of myocytes are separated by collagen
(interstitial ﬁbrosis). Nuclei are enlarged and hypertrophic, consistent with myocardial hypertrophy. The sarcoplasm contains focal vacuoles
(arrow). The resected apical core showed identical ﬁndings. Hematoxylin and eosin 200. (F) Electron microscopy of cardiac biopsy.
Cardiac myocytes show vacuolar spaces and increased lipofuscin, consistent with cardiomyopathy due to cobalt toxicity (1). Please see
Online Videos 1 and 2.
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APPENDIX For supplemental videos and their legends, please see
the online version of this article.Presence of Ischemia by FFR Without
Signiﬁcant Anatomic Stenosis Is Likely due
to Concomitant Diffuse Disease and Not
due to Impaired Vasodilation From
Pharmacological StressThe editorial (1) commenting on the paper by Park et al.
(2) in the January 2015 issue of iJACC addressed
the discordance between measured % diameter ste-
nosis of the coronary artery disease (CAD) lesion by
computed tomography angiography (CTA) and the
presence of ischemia by invasive fractional ﬂow
reserve (FFR) of <0.8, and concordance with high-risk
plaque characteristics by CTA (volume, low attenua-
tion, and positive remodeling). The pathway was
reviewed, from atherosclerosis leading to endothelial
dysfunction and impaired vasodilation response
to physiological and pharmacological stress (i.e.,
microvascular dysfunction [MVD]), which would
add to the maximal ﬂow limitation imposed by the
